Literature DB >> 28285028

Social cognition of patients with schizophrenia across the phases of illness - A longitudinal study.

Vijaya Lakshmi Valaparla1, Ritu Nehra2, Urvakhsh Meherwan Mehta3, Jagadisha Thirthalli3, Sandeep Grover4.   

Abstract

AIM: This longitudinal study aimed to evaluate social cognition of patients with schizophrenia at two points, i.e., during the symptomatic phase and clinical remission phase. Additional aim was to evaluate the relationship of social cognition with psychopathology and functional outcome.
METHODOLOGY: Fifty-one patients (N=51) were evaluated on Social Cognition Rating Tools in Indian Setting (SOCRATIS), Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Socio-occupational functioning scale (SOFS) and Indian Disability Evaluation and Assessment Scale (IDEAS) during the symptomatic phase of illness. These patients were followed-up longitudinally for achieving clinical remission. Out of the 51 patients, 32 patients underwent second assessment after a mean duration of 143 (SD 34.9) days, while in clinical remission. Data of 111 healthy controls was used for comparison.
RESULTS: Social cognitive deficits were present in both the phases of illness. However, when the baseline and follow-up data was compared, it was evident that the severity of social cognition deficits is lower during the clinical remission phase. Higher levels of social cognitive deficits in both phases of illness are associated with higher socio-occupational dysfunction and higher disability.
CONCLUSION: Present study suggests that impairment in social cognition in patients with schizophrenia is present both in symptomatic and remission phase, with higher level of deficits during the symptomatic phase. Social cognition impairments are associated with poor social and occupational functioning and higher level of disability.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Disability; Functioning; Schizophrenia; Social cognition

Mesh:

Year:  2017        PMID: 28285028     DOI: 10.1016/j.schres.2017.03.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Social cognition in siblings of patients with bipolar disorders.

Authors:  Swati Choudhary; B N Subodh; Sandeep Grover
Journal:  Ind Psychiatry J       Date:  2021-06-24

2.  Functional Impairments and Theory of Mind Deficits in Schizophrenia: A Meta-analysis of the Associations.

Authors:  Élisabeth Thibaudeau; Caroline Cellard; Mélissa Turcotte; Amélie M Achim
Journal:  Schizophr Bull       Date:  2021-04-29       Impact factor: 9.306

3.  Social cognition in schizophrenia.

Authors:  Nare Torosyan; Robert G Bota
Journal:  Ment Illn       Date:  2017-10-19

4.  The difference of social cognitive and neurocognitive performance between patients with schizophrenia at different stages and influencing factors.

Authors:  Shengyun Chen; Yaxi Liu; Dennis Liu; Guican Zhang; Xiaoli Wu
Journal:  Schizophr Res Cogn       Date:  2021-02-25

5.  Social cognition in patients with first episode of psychosis in remission.

Authors:  Mahadev Singh Sen; Ritu Nehra; Sandeep Grover
Journal:  Indian J Psychiatry       Date:  2020-10-10       Impact factor: 1.759

6.  The French Integrative Psychosocial Rehabilitation Assessment for Complex Situations (FIPRACS): Modelization of an Adapted Assessment Method Toward Long-Term Psychiatric Inpatients With Disabling, Severe and Persistent Mental Illness.

Authors:  Christophe Clesse; S Salime; I Dumand; S Barbier Concetta-Ciciarelli; S Lavenir; K Kacemi; P Heckel-Chalet; Frank Sissung; Aurore Poinsignon; Anthony Simon; M Decker; M Batt
Journal:  Front Psychiatry       Date:  2020-09-18       Impact factor: 4.157

Review 7.  Metacognition, social cognition, and mentalizing in psychosis: are these distinct constructs when it comes to subjective experience or are we just splitting hairs?

Authors:  P H Lysaker; S Cheli; G Dimaggio; B Buck; K A Bonfils; K Huling; C Wiesepape; J T Lysaker
Journal:  BMC Psychiatry       Date:  2021-07-02       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.